Literature DB >> 22454045

Acute versus chronic hypoxia in tumors: Controversial data concerning time frames and biological consequences.

C Bayer1, P Vaupel.   

Abstract

BACKGROUND: Many tumors contain hypoxic regions. Hypoxia, in turn, is known to increase aggressiveness and to be associated with treatment resistance. The two most frequently described and investigated subtypes of tumor hypoxia are acute and chronic. These two subtypes can lead to completely different hypoxia-related responses within the tumor, which could have a direct effect on tumor development and response to treatment. In order to accurately assess the specific biological consequences, it is important to understand which time frames best define acute and chronic hypoxia.
MATERIALS AND METHODS: This article provides an overview of the kinetics of in vitro and in vivo acute and chronic tumor hypoxia. Special attention was paid to differentiate between methods to detect spontaneous in vivo hypoxia and to describe the biological effects of experimental in vitro and in vivo acute and chronic tumor hypoxia. RESULTS AND
CONCLUSIONS: There are large variations in reported spontaneous fluctuations in acute hypoxia that are dependent on the cell lines investigated and the detection method used. In addition to differing hypoxia levels, exposure times used to induce in vitro and in vivo experimental acute and chronic hypoxia range from 30 min to several weeks with no clear boundaries separating the two. Evaluation of the biological consequences of each hypoxia subtype revealed a general trend that acute hypoxia leads to a more aggressive phenotype. Importantly, more information on the occurrence of acute and chronic hypoxia in human tumors is needed to help our understanding of the clinical consequences.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22454045     DOI: 10.1007/s00066-012-0085-4

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  94 in total

1.  Hemodynamic characteristics in microcirculatory blood channels during early tumor growth.

Authors:  B Endrich; M Intaglietta; H S Reinhold; J F Gross
Journal:  Cancer Res       Date:  1979-01       Impact factor: 12.701

2.  Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation.

Authors:  J M Brown
Journal:  Br J Radiol       Date:  1979-08       Impact factor: 3.039

3.  Comparison of (immuno-)fluorescence data with serial [¹⁸F]Fmiso PET/CT imaging for assessment of chronic and acute hypoxia in head and neck cancers.

Authors:  Constantin-Alin Maftei; Kuangyu Shi; Christine Bayer; Sabrina T Astner; Peter Vaupel
Journal:  Radiother Oncol       Date:  2011-06-28       Impact factor: 6.280

4.  Feedback regulators of hypoxia-inducible factors and their role in cancer biology.

Authors:  Anne-Theres Henze; Till Acker
Journal:  Cell Cycle       Date:  2010-07-30       Impact factor: 4.534

5.  Hypoxia in human colorectal adenocarcinoma: comparison between extrinsic and potential intrinsic hypoxia markers.

Authors:  Laurence Goethals; Annelies Debucquoy; Christiaan Perneel; Karel Geboes; Nadine Ectors; Harlinde De Schutter; Freddy Penninckx; William H McBride; Adrian C Begg; Karin M Haustermans
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-05-01       Impact factor: 7.038

Review 6.  Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis.

Authors:  Peter Vaupel
Journal:  Oncologist       Date:  2008

Review 7.  Relationships between cycling hypoxia, HIF-1, angiogenesis and oxidative stress.

Authors:  Mark W Dewhirst
Journal:  Radiat Res       Date:  2009-12       Impact factor: 2.841

8.  Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix.

Authors:  M Höckel; C Knoop; K Schlenger; B Vorndran; E Baussmann; M Mitze; P G Knapstein; P Vaupel
Journal:  Radiother Oncol       Date:  1993-01       Impact factor: 6.280

9.  Acute hypoxia enhances spontaneous lymph node metastasis in an orthotopic murine model of human cervical carcinoma.

Authors:  Rob A Cairns; Richard P Hill
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

10.  Transient perfusion in human melanoma xenografts.

Authors:  I Tufto; E K Rofstad
Journal:  Br J Cancer       Date:  1995-04       Impact factor: 7.640

View more
  60 in total

1.  Berberine enhances radiosensitivity of esophageal squamous cancer by targeting HIF-1α in vitro and in vivo.

Authors:  Xi Yang; Baixia Yang; Jing Cai; Chi Zhang; Qu Zhang; Liping Xu; Qin Qin; Hongcheng Zhu; Jianxin Ma; Guangzhou Tao; Hongyan Cheng; Xinchen Sun
Journal:  Cancer Biol Ther       Date:  2013-09-12       Impact factor: 4.742

Review 2.  Cellular and molecular mechanisms underlying oxygen-dependent radiosensitivity.

Authors:  Chao Liu; Qun Lin; Zhong Yun
Journal:  Radiat Res       Date:  2015-05-04       Impact factor: 2.841

3.  Fast dynamic electron paramagnetic resonance (EPR) oxygen imaging using low-rank tensors.

Authors:  Anthony G Christodoulou; Gage Redler; Bryan Clifford; Zhi-Pei Liang; Howard J Halpern; Boris Epel
Journal:  J Magn Reson       Date:  2016-07-15       Impact factor: 2.229

4.  Robotic radiosurgery as an alternative to brachytherapy for cervical cancer patients.

Authors:  Oliver Neumann; Anne Kluge; Olga Lyubina; Waldemar Wlodarczyk; Ulrich Jahn; Christhardt Köhler; Volker Budach; Markus Kufeld; Simone Marnitz
Journal:  Strahlenther Onkol       Date:  2014-03-04       Impact factor: 3.621

5.  Paeonol enhances the sensitivity of human ovarian cancer cells to radiotherapy-induced apoptosis due to downregulation of the phosphatidylinositol-3-kinase/Akt/phosphatase and tensin homolog pathway and inhibition of vascular endothelial growth factor.

Authors:  Hai-Mei Zhou; Qin-Xiang Sun; Yan Cheng
Journal:  Exp Ther Med       Date:  2017-08-03       Impact factor: 2.447

Review 6.  Imaging tumor hypoxia to advance radiation oncology.

Authors:  Chen-Ting Lee; Mary-Keara Boss; Mark W Dewhirst
Journal:  Antioxid Redox Signal       Date:  2014-03-24       Impact factor: 8.401

7.  A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer. Osteopontin, carbonic anhydrase IX and vascular endothelial growth factor.

Authors:  C Ostheimer; M Bache; A Güttler; M Kotzsch; D Vordermark
Journal:  Strahlenther Onkol       Date:  2013-12-11       Impact factor: 3.621

Review 8.  Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response.

Authors:  S R McKeown
Journal:  Br J Radiol       Date:  2014-03       Impact factor: 3.039

9.  Association of genetic variants in VEGF-A with clinical recurrence in prostate cancer patients treated with definitive radiotherapy.

Authors:  T Langsenlehner; E-M Thurner; W Renner; A Gerger; K S Kapp; U Langsenlehner
Journal:  Strahlenther Onkol       Date:  2014-01-18       Impact factor: 3.621

10.  The anti-protozoan drug nifurtimox preferentially inhibits clonogenic tumor cells under hypoxic conditions.

Authors:  Quhuan Li; Qun Lin; Hoon Kim; Zhong Yun
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.